Szemészet, 2022 (159. évfolyam, 1-4. szám)

2022-06-01 / 2. szám

Proliferativ vitreoretinopathia 28(5): 576-580. https://doi.org/10.1038/eye.2014.21 87 16. Grigoropoulos VG, Benson S, Bunce C, Charteris DG. Functional outco­me and prognostic factors in 304 eyes managed by retinectomy. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 2007; 245(5): 641-648. https://doi.org/10.1007/s00417-006-0478-z 17. Heffer AM, Wang V, Libby RT, Feldon SE, Woeller CF, Kuriyan AE. (2020) Salinomycin inhibits proliferative vitreoretinopathy formation in a mouse model. PloS one 15(12): e0243626. https://doi.org/10.1371/journal.pone.0243626 18. Heimann H, Bartz-Schmidt KU, Bornfeld N, et al. Scleral buckling ver­sus primary vitrectomy in rhegmatogenous retinal detachment: a prospe­ctive randomized multicenter clinical study. Ophthalmology 2007; 114(12): 2142-2154. https://doi.Org/10.1016/j.ophtha.2007.09.013 19. Israilevich RN, Starr MR, Mahmoudzadeh R, Salabati M, Swaminathan V, Huang D, Kuriyan AE, Yonekawa Y, Garg SJ, Mehta S, Regillo CD, Hsu J. Factors Associated with Good Visual Acuity Outcomes After Retinectomy in Eyes with Proliferative Vitreoretinopathy. Am J Ophthalmol 2022 Mar 11: S0002-9394(22)00096-4. https://doi.Org/10.1016/j.ajo.2022.02.028 20. Iwahashi-Shima C, Sato T, Bando H, Ikeda T, Emi K. Anatomic and functi­onal outcomes of 25-gauge vitrectomy for repair of eyes with rhegmatog­enous retinal detachment complicated by proliferative vitreoretinopathy. Clin Ophthalmol Auckl NZ 2013; 7: 2043-2049. https://doi.org/10.2147/OPTH.S52260 21. Joeres S, Kirchhof B, Joussen AM. PVR as a complication of rhegman­­togenous retinal detachement: a solved problem? Br J Ophthalmol 2006; 90(6): 796-797. https://doi.org/10.1136/bjo.2005.088856 22. Kawahara S, Hata Y, Kita T, Arita R, Miura M, Nakao S, Mochizuki Y, et al. Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. Diabetes 2008; 57(10): 2784-93. https://doi.org/10.2337/db08-0302 23. Khan MA, Kuley A, Riemann CD, et al. Long-Term Visual Outcomes and Safety Profile of 27-Gauge Pars Plana Vitrectomy for Posterior Segment Disease. Ophthalmology 2018; 125(3): 423-431. https://doi.Org/10.1016/j.ophtha.2017.09.013 24. Kunikata H, Yasuda M, Aizawa N, Tanaka Y, Abe T, Nakazawa T. Intraocu­lar concentrations of cytokines and chemokines in rhegmatogenous retinal detachment and the effect of intravitreal triamcinolone acetonide. Ameri­can journal of ophthalmology 2013; 155(6): 1028—37.e1. https://doi.Org/10.1016/j.ajo.2013.01.013 25. won OW, Song JH, Roh Ml. Retinal detachment and proliferative vitreo­retinopathy. Dev Ophthalmol 2016; 55: 154-162. https://doi.org/10.1159/000438972 26. Lean JS, Stern WH, Irvine AR, Azen SP. Classification of prolifera­tive vitreoretinopathy used in the silicone study. The Silicone Study Group. Ophthalmology 1989; 96(6): 765-771. https://doi.org/10.1016/s0161—6420(89332821—1 27. Leiderman Yl, Miller JW. Proliferative vitreoretinopathy: pathobiology and therapeutic targets. Semin Ophthalmol 2009; 24(2): 62-69. https://doi.org/10.1080/08820530902800082 28. Machemer R, et al. An updated classification of retinal detachment with proliferative vitreoretinopathy. American journal of ophthalmology 1991; 112(2): 159-65. https://doi.Org/10.101 B/s0002-9394(14)76695-4 29. Mysore Y, Del Amo EM, Loukovaara S, Hagström M, Urtti A, Kauppinen A. Statins for the prevention of proliferative vitreoretinopathy: cellular res­ponses in cultured cells and clinical statin concentrations in the vitreous. Sei Rep 2021; 11(1): 980. https://doi.org/10.1038/s41598-020-80127-1. 30. Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res 1998; 17(1): 77-98. https://doi.org/10.1016/s1350-9462(97)00007-4 31. Oellers P, Stinnett S, Hahn P. Valved versus nonvalved cannula small-gauge pars plana vitrectomy for repair of retinal detachments with Grade C proliferative vitreoretinopathy. Clin Ophthalmol Auckl NZ 2016; 10:1001-1006. https://doi.org/10.2147/OPTH.S104901 32. Papp A, Lendvai Zs, Szalai I, Resch M. Hagyományos bedomborító mű­tétek eredményei rhegmatogén ideghártya-leválások esetén. Szemészet 2012; 149: (3) 152-154. 33. Papp A, Resch M. A foveát nem érintő „makula-on” ideghártya-leválá­sok műtéti sürgősségéről. Szemészet 2019; 156:127-133 34. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthal­mol. 1998; 43(1): 3-18. https://doi.Org/10.1016/s0039-6257(98)00023-x 35. Pastor JC, de la Rúa ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 2002; 21(1): 127-144. https://doi.org/10.1016/s1350-9462(01)00023-4 36. Patel SN, Salabati M, Mahmoudzadeh R, Obeid A, Kuriyan AE, Yone­kawa Y, Klufas MA, Garg SJ, Hsu J, Khan MA. Surgical failures after prima­ry scleral buckling for rhegmatogenous retinal detachment: Comparison of Eyes With and Without Proliferative Vitreoretinopathy. Retina 2021 Nov 1; 41(11): 2288-2295. https://doi.org/10.1097/IAE.0000000000003214 37. Pennock S, Haddock LJ, Mukai S, Kazlauskas A. Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor a to promote proliferative vitreoretinopathy. Am J Pathol 2014; 184(11): 3052-3068. https://doi.Org/10.1016/j.ajpath.2014.07.026 38. Quiram PA, Gonzales CR, Hu W, et al. Outcomes of Vitrectomy with Inferior Retinectomy in Patients with Recurrent Rhegmatogenous Retinal Detachments and Proliferative Vitreoretinopathy. Ophthalmology 2006; 113(11): 2041-2047. https://doi.Org/10.1016/j.ophtha.2006.05.039 39. Rao RC, Blinder KJ, Smith BT, Shah GK. Internal limiting membrane peeling for primary rhegmatogenous retinal detachment repair. Ophthalmology 2013; 120(5): 1102-1103.e1-2. https://doi.Org/10.1016/j.ophtha.2012.12.010 40. Read SP, Aziz HA, Kuriyan A, et al. Retinal detachment surgery in a pediatric population: visual and anatomic outcomes. Retina 2018; 38 (7): 1393-1402. https://doi.org/10.1097/IAE.0000000000001725 41. Resch MD, Balogh A, Lászik G, Nagy ZZ, Papp A. Association betwe­en retinal vessel density and postoperative time after primary repair of rhegmatogenous retinal detachment. Plos one 2021; 16 (10), e0258126 https://doi.org/10.1371/journal.pone.0258126 42. Resch M, Seres A, Maneschg 0, Pregun T, Papp A, Szabó A, Németh J. A nehéz szilikonolaj a retinaleválás sebészetében. Szemészet 2010; 147: 155-161. 43. Resch M, Barcsay Gy, Szabó A, Papp A. A retinaleválás korszerű ellá­tása. Mária utcai füzetek 2015; 1: 3-27. 44. Sadaka A, Sisk RA, Osher JM, Toygar 0, Duncan MK, Riemann CD. Int­ravitreal methotrexate infusion for proliferative vitreoretinopathy. Clinical ophthalmology 2016; 10:1811-7. https://doi.org/10.2147/0PTH.S111893 45. Sadaka A, Giuliari GP. Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol 2012; 6: 1325-1333. https://doi.org/10.2147/0PTH.S27896 46. Sato T, Emi K, Bando H, Ikeda T. Retrospective comparison of 25-gauge vitrectomy for repair of proliferative vitreoretinopathy with or without anterior proliferation. Graefes Arch Clin Exp Ophthalmol Albrecht Von Gra­efes Arch Klin Exp Ophthalmol 2014; 252(12): 1895-1902. https://doi.org/10.1007/s00417-014-2846-5 47. Soós J, Resch MD, Berkó S, Kovács A, Katona G, Facskó A, Csányi E, Budai-Szűcs M. Comparison of hydrophilic ophthalmic media on silicone oil emulsification. PLoS One 2020 Jun 19; 15(6): e0235067. https://doi.org/10.1371/journal.pone.0235067 48. The classification of retinal detachment with proliferative vitreoretino­pathy. Ophthalmology 1983; 90(2): 121-125. https://doi.org/10.1016/s0161-6420(83)34588-7 49. Tousi A, Hasanpour H, Soheilian M. Intravitreal Injection of Bevacizu­­mab in Primary Vitrectomy to Decrease the Rate of Retinal Redetachment: A Randomized Pilot Study. J Ophthalmic Vis Res 2016; 11(3): 271-276. https://doi.org/10.4103/2008-322X.188390 (PubMed: 27621784) 50. Tseng JJ, Barile GR, Schiff WM, Akar Y, Vidne-Hay 0, Chang S. Influen­ce of relaxing retinotomy on surgical outcomes in proliferative vitreoreti­nopathy. Am J Ophthalmol 2005; 140(4): 628-636. https://doi.Org/10.1016/j.ajo.2005.04.021 51. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight hepa­rin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 2007; 114(4): 698-704. https://doi.Org/10.1016/j.ophtha.2006.08.042 52. Yannuzzi NA, Callaway NF, Sridhar J, Smiddy WE. Internal limiting­­membrane peelingduring pars plana vitrectomy for rhegmatogenous reti­nal detachment: cost analysis, reviewof the literature, and meta-analysis. Retina 2018; 38: 2081-2087. https://doi.org/10.1097/IAE.0000000000002248 Levelez Dn Resch Miklós, 1085 Budapest, Mária u. 39. E-mail: miklosresch@gmail.com

Next

/
  • Layout
  • Zoom
  • Rotation
Thumbnails
Contents